BMC Medicine
July 6, 2026
Hannah Adler, Rebecca Filipic, Dr Maria Gonzalez et al.
BACKGROUND: Existential distress is commonly experienced by people with cancer, yet there are limited treatment options. The therapeutic potential for psychedelic-assisted therapy (PAT) utilising psilocybin for this cohort is underexplored, with emerging literature showing clinical improvements in wellbeing. In Australia there is limited knowledge on healthcare professionals' (HCPs') attitudes,...
Scientific Reports
November 20, 2025
Daniel Perkins, Andreas Halman, Anna Urokohara et al.
Acute subjective experiences induced by psychedelics have been identified as important mediators of therapeutic outcomes in many studies. Mystical experiences specifically, have been correlated with a range of therapeutic outcomes including reductions in symptoms of depression, anxiety and addiction. This paper assesses acute subjective experiences induced by an encapsulated DMT-harmala...
Front Psychiatry
August 15, 2025
Yvonne Bonomo, Amanda F. Norman, Lisa Collins et al.
1 citation
Introduction: Ayahuasca is a psychedelic compound of N, N, Dimethyltryptamine (DMT) and harmala alkaloids used for spiritual and medicinal applications in traditional settings. A range of potential psychotherapeutic mechanisms have been proposed for ayahuasca. These are thought to contribute to improvements in various psychiatric conditions including mood disorders and substance dependence....
BMJ Open
April 1, 2025
Vanessa L. Beesley, Tom Kennedy, Fiona Maccallum et al.
2 citations
Introduction Prolonged grief disorder (PGD) represents a substantial public health issue, especially in oncology settings where it affects up to 30% of bereaved carers. Current best-practice treatments are lengthy, and up to 50% of participants have persistent PGD. Building on encouraging recent research with psychedelic-assisted therapies, the Psilocybin-Assisted suppoRtive psychoTherapy IN...
Forensic Chemistry
March 25, 2025
Pragna Gaur, Liam Engel, Damian Robert Hall et al.
1 citation
Commencements of clinical trials of psychedelic therapies for intractable forms of mental illnesses have drawn increased public attention to plants containing psychedelic substances. Whilst the psychoactive alkaloid mescaline has limited clinical trials, the San Pedro ( Trichocereus spp.) cacti from which it is found have a long history of Indigenous medical and spiritual use. Traditional use...
Journal of Psychoactive Drugs
February 20, 2025
Broc A. Pagni, Andreas Halman, Jerome Sarris et al.
7 citations
The durability of ayahuasca's effects on mental health and the influence of clinical diagnoses on therapeutic response is unclear. Adults with no prior exposure to ayahuasca (n = 66) participating in neo-shamanic ayahuasca ceremonies completed questionnaires at baseline, 7 days, and 1, 6, and 12 months. Mixed models were used to characterize temporal trajectories in mental health, alcohol and...
PLOS mental health
2025
Óscar Andión, José Carlos Bouso, Jerome Sarris et al.
1 citation
Ayahuasca is a decoction native to the Amazon, where it plays a central role in the traditional medicine of many local cultures and has expanded internationally over the last decades. Ayahuasca has also attracted the interest of scientists for its potential benefits on mental health, but its adverse effects are under-researched. We analyzed data from the Global Ayahuasca Survey, including...
Journal of Psychoactive Drugs
November 23, 2024
Daniel Perkins, Jerome Sarris, Tessa Cowley-Court et al.
5 citations
Emerging evidence indicates that ayahuasca consumption may have beneficial mental health effects. This study undertakes the largest analysis to date of associations between naturalistic ayahuasca use and current mental health status via an online cross-sectional survey. The sample included 7,576 participants (average age 41, 47% female) who had consumed ayahuasca in religious, traditional, or...
Clinical Pharmacology & Therapeutics
September 30, 2024
Andreas Halman, Rachel Conyers, Claire Moore et al.
13 citations
Psychedelics have recently re‐emerged as potential treatments for various psychiatric conditions that impose major public health costs and for which current treatment options have limited efficacy. At the same time, personalized medicine is increasingly being implemented in psychiatry to provide individualized drug dosing recommendations based on genetics. This review brings together these...
Annals of the New York Academy of Sciences
September 23, 2024
Jerome Sarris, Andreas Halman, Anna Urokohara et al.
6 citations
Artificial intelligence (AI) and psychedelic medicines are among the most high-profile evolving disruptive innovations within mental healthcare in recent years. Although AI and psychedelics may not have historically shared any common ground, there exists the potential for these subjects to combine in generating innovative mental health treatment approaches. In order to inform our perspective,...
International journal of toxicology
2024
Eleanor White, Tom Kennedy, Simon Ruffell et al.
13 citations
The objective of this paper is to conduct a systematic thematic review of adverse events, safety, and toxicity of traditional ayahuasca plant preparations and its main psychoactive alkaloids (dimethyltryptamine [DMT], harmine, harmaline, and tetrahydroharmine), including discussing clinical considerations (within clinical trials or approved settings). A systematic literature search of...
Drug Science Policy and Law
2024
Simon Ruffell, Sam Gandy, WaiFung Tsang et al.
10 citations
Indigenous Amazonian shamanic ayahuasca practice is embedded in a nature-based context and is employed as an ecological mediating agent and in collective environmental decision-making processes by some of the groups that use it. Phenomenologically, the ayahuasca experience is often rich in nature-based themes and content, and its usage has been associated with eliciting shifts in perspectives...
PCN reports : psychiatry and clinical neurosciences
December 1, 2023
Simon Ruffell, Max Crosland-Wood, Rob Palmer et al.
37 citations
Ayahuasca is a psychedelic plant brew originating from the Amazon rainforest. It is formed from two basic components, the Banisteriopsis caapi vine and a plant containing the potent psychedelic dimethyltryptamine (DMT), usually Psychotria viridis. Here we review the history of ayahuasca and describe recent work on its pharmacology, phenomenological responses, and clinical applications. There...
Journal of Psychopharmacology
November 20, 2023
Andreas Halman, Geraldine Kong, Jerome Sarris et al.
42 citations
Classic psychedelics, including lysergic acid diethylamide (LSD), psilocybin, mescaline, N,N-dimethyltryptamine (DMT) and 5-methoxy-N,N-dimethyltryptamine (5-MeO-DMT), are potent psychoactive substances that have been studied for their physiological and psychological effects. However, our understanding of the potential interactions and outcomes when using these substances in combination with...
Psychoactives
October 3, 2023
Daniel Perkins, Emérita Sátiro Opaleye, José Carlos Bouso et al.
18 citations
Background: In the context of increasing scientific interest in the potential therapeutic use of psychedelic agents and their underlying psychotherapeutic mechanisms, we undertake the first detailed assessment of insights and life and lifestyle changes associated with ayahuasca consumption. Methods: An international cross-sectional study of ayahuasca drinkers in a variety of settings was...
Psychoactives
June 13, 2023
Tessa Cowley-Court, Richard Chenhall, Jerome Sarris et al.
19 citations
Ayahuasca is an Amazonian psychoactive plant medicine being explored for its potential therapeutic uses in Western contexts. Preliminary studies link ayahuasca use with improvements across a range of mental health indicators, but studies have not yet explored qualitative aspects of the post-treatment process known in the psychedelic literature as “integration”. This includes how participants...
medRxiv
June 1, 2023
Andreas Halman, Geraldine Kong, Jerome Sarris et al.
17 citations
preprint
Abstract Classic psychedelics, lysergic acid diethylamide, psilocybin, mescaline and N,N-dimethyltryptamine, are potent psychoactive substances that have been studied for their physiological and psychological effects. However, our understanding of the potential interactions and outcomes of using these substances are used in combination with other psychoactive drugs is limited. This systematic...
Psychedelics as Psychiatric Medications
March 1, 2023
Daniel Perkins, Simon Ruffell, Jerome Sarris
Abstract Ayahuasca is a psychedelic plant brew originating in the Amazon basin. It is typically made from two basic components: the ayahuasca vine (Banisteriopsis caapi), containing various harmala alkaloids, and the leaves of a plant containing the potent psychedelic dimethyltryptamine (DMT), such as the chacruna plant (Psychotria viridis). Evidence suggests the brew has been used for at least...
Frontiers in Neuroscience
January 31, 2023
Daniel Perkins, Kimberley Day, Jerome Sarris et al.
27 citations
Ayahuasca is a psychoactive Amazonian plant brew. It is usually made from the Banisteriopsis caapi vine (Spruce ex Griseb. Morton, Malpighiaceae), which contains three primary harmala alkaloids, along with the leaves of Psychotria viridis (Ruiz et Pavon, Rubiaceae) in which the potent psychedelic dimethyltryptamine (DMT) is found. DMT-harmaloid concoctions have gained popularity in recent...
Frontiers in Psychiatry
December 5, 2022
Geovan Menezes de Sousa, Vagner Deuel de Oliveira Tavares, Ana Cecília de Menezes Galvão et al.
14 citations
Introduction The understanding of biological responses to psychedelics with antidepressant potential is imperative. Here we report how a set of acute parameters, namely emotional (depressive symptoms), cognitive (psychedelic experience), and physiological (salivary cortisol), recorded during an ayahuasca dosing session, modulated serum brain-derived neurotrophic factor (BDNF), serum cortisol...
The International Journal of Neuropsychopharmacology
October 21, 2022
James J Gattuso, Daniel Perkins, Simon Ruffell et al.
233 citations
Abstract Psychedelics are a unique class of drug that commonly produce vivid hallucinations as well as profound psychological and mystical experiences. A grouping of interconnected brain regions characterized by increased temporal coherence at rest have been termed the Default Mode Network (DMN). The DMN has been the focus of numerous studies assessing its role in self-referencing, mind...
Annals of the New York Academy of Sciences
March 1, 2022
Jerome Sarris
12 citations
Disruptive innovation is a cornerstone of various disciplines, particularly in the business world, where paradigm-altering approaches are often lauded. As a construct, disruptive psychiatry can be considered to embody such an approach by the pursuit of innovations within the field which test boundaries and shake up the status quo. Given the importance of addressing the current mental health...
February 14, 2022
Daniel Perkins, Simon Ruffell, Kimberley Day et al.
1 citation
preprint
Ayahuasca is a psychoactive Amazonian plant brew. It is usually made from the Banisteriopsis caapi vine, which contains three primary harmala alkaloids, along with the leaves of Psychotria viridis in which the potent psychedelic dimethyltryptamine (DMT) is found. DMT-harmaloid concoctions have gained popularity in recent years, due to growing anecdotal and scientific reports of therapeutic...
PLOS global public health
2022
José Carlos Bouso, Óscar Andión, Jerome Sarris et al.
115 citations
Ayahuasca is a plant-based decoction native to Amazonia, where it has a long history of use in traditional medicine. Contemporary ritual use of ayahuasca has been expanding throughout the world for mental health purposes, and for spiritual and personal growth. Although researchers have been conducting clinical trials and observational studies reporting medical and psychological benefits, most...
Frontiers in Pharmacology
2022
Daniel Perkins, Broc A. Pagni, Jerome Sarris et al.
53 citations
Background: Naturalistic and placebo-controlled studies suggest ayahuasca, a potent psychedelic beverage originating from Indigenous Amazonian tradition, may improve mental health, alter personality structure, and reduce alcohol and drug intake. To better understand ayahuasca's therapeutic potential and to identify factors that influence therapeutic efficacy, we conducted a naturalistic,...